Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosis  by Taniguchi, M. et al.
Persistent hyperparathyroidism in renal allograft
recipients: Vitamin D receptor, calcium-sensing
receptor, and apoptosis
M Taniguchi1, M Tokumoto1, D Matsuo1, K Motoyama2, A Sugitani2, S Kuroki2, H Yotsueda1, K Tsuruya1,
H Hirakata3 and M Iida1
1Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Department
of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan and 3Kidney Care Unit, Kyushu
University Hospital, Fukuoka, Japan
The phenotypic changes in parathyroid cells after successful
renal transplantation remain to be elucidated. We compared
10 diffuse and 11 nodular hyperplastic parathyroid glands
from five renal allograft recipients with persistent
hyperparathyroidism, with five diffuse and 13 nodular
hyperplasia from seven uremic patients on hemodialysis, and
13 normal glands. Comparisons included expressions of both
vitamin D receptor (VDR) and calcium-sensing receptor
(CaSR), proliferative activity (Ki67), and apoptosis (TUNEL).
Immunoreactivity was assessed semiquantitatively and
expressed as labeling index. The area/cell was also measured
to assess cellular hypertrophy. The labeling indexes of VDR
(587771; mean7s.e.m.) and CaSR (45.072.8) in recipients’
diffuse hyperplasia were significantly higher than those in
uremic diffuse hyperplasia (224744, 29.372.3, respectively)
(Po0.01, each). However, these expressions remained low in
recipients’ nodular hyperplasia (4278, 11.871.4,
respectively). Ki67 labeling index in recipients’ nodular
hyperplasia (771) was significantly smaller than in uremic
patients (2476, Po0.01). TUNEL labeling index in recipients’
diffuse hyperplasia (3075) was the highest among the
groups. The cell volume tended to be smaller in both
patterns of hyperplasia in allograft recipients compared with
uremic patients. Our results suggest that the phenotypic
change in parathyroid cells after renal transplantation
depends on the pattern of hyperplasia, where it is normalized
only in diffuse hyperplastic glands in which the number of
cells also regresses with significant induction of apoptosis.
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Secondary hyperparathyroidism is the major complication in
patients with chronic renal disease, and the main pathogenic
factors include the deficiency of active vitamin D production,
hypocalcemia, and phosphorus retention. The sustained
hyperfunction of the parathyroid gland is attributable to
the progressive proliferation of parathyroid cells. Immuno-
histochemical analyses have revealed the downregulation of
vitamin D receptor (VDR), calcium-sensing receptor (CaSR),
and the cyclin-dependent kinase inhibitor, p21 and p27, and
the upregulation of transforming growth factor-a in resected
glands from animal models and hemodialysis patients.1–9
These phenotypic alterations of parathyroid cells develop
during the earlier course of chronic renal disease,1,8,9 and
parathyroid hyperplasia changes its pattern from diffuse to
nodular one.5
In most cases, the biochemical disorders normalize within
the first month after successful renal transplantation, in
association with the normalization of parathyroid function
within 12 months.10–14 However, even with achievement of
normal renal function, persistent hyperparathyroidism can
still be recognized in some allograft recipients, requiring
parathyroidectomy.14–19 In these patients, excessive parathyr-
oid hormone (PTH) secretion continues, which enhances
calcium (Ca) re-absorption and phosphorus (Pi) excretion
via the transplanted kidney, leading to hypercalcemia and
hypophosphatemia. The restoration of active vitamin D
synthesis and improvement of skeletal resistance to PTH may
also accelerate hypercalcemia. It has been reported that renal
allograft recipients with persistent secondary hyperpara-
thyroidism tend to have a history of longer duration of
hemodialysis and a higher level of PTH at the time of renal
transplantation,10,20 suggesting that persistent hyperpara-
thyroidism is largely dependent on parathyroid gland
volume, that is, the pattern of hyperplasia.21,22
There is still uncertainty about regression of parathyroid
hyperplasia after successful renal transplantation. Lewin
et al.23 suggested that in spite of the rapid reversibility of
parathyroid function after renal transplantation in uremic
rats, parathyroid gland regression does not contribute to this
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reversibility, although no histological data were presented to
prove this. On the other hand, Bonarek et al.13 reported a
significant decrease in the mean maximal PTH levels at 6
months after renal transplantation, suggesting that the
improvement of parathyroid function was mainly owing to
reduction of its functional mass. Normal parathyroid cells are
known to show an extremely low turnover, their mean
lifespan being approximately 2 years in adult rats24 and 20
years in humans.25 Interestingly, the rate of proliferation of
hyperplastic parathyroid tissue of uremic patients is reported
to be higher than that of apoptosis.26,27 Thus, Parfitt28
expected that the regression after kidney transplantation
must be an extremely slow process, and if it occurs, apoptosis
may be involved. However, there are no data on changes in
parathyroid cell number and cell hypertrophy after successful
renal transplantation.
The present study was designed to determine the
mechanism of persistent hyperparathyroidism in renal
allograft recipients. For this purpose, we examined the
phenotypic changes of parathyroid cells, in terms of
expressions of VDR and CaSR, in the resected glands from
renal allograft recipients who have had more than one
hyperplastic nodules and finally underwent parathyroidec-
tomy owing to severe persistent hyperparathyroidism. The
second aim of the study was to assess the balance between cell
proliferation and apoptosis in these resected glands.
RESULTS
Biochemical data and weight of resected glands
As depicted in Table 1, the preoperative level of corrected
serum Ca was significantly highest in allograft recipients with
persistent hyperparathyroidism, followed by those in uremic
patients and the control subjects. Serum Pi was high in
hemodialysis patients, followed by control subjects, and was
lowest in allograft recipients. Serum alkaline phosphatase and
intact PTH were higher in the recipients than those of other
groups. Among five recipients, endogenous 1,25-dihydroxy-
vitamin D3 was measured in only one recipient, which was
53 pg/ml (within normal range).
The gland weight was heavier in uremic nodular
hyperplasia and recipients with nodular hyperplasia, followed
by those with diffuse hyperplasia of both groups (Table 2).
Histopathological examination revealed that all the renal
allograft recipients who underwent parathyroidectomy had at
least more than one nodular hyperplastic glands.
Expressions of VDR and CaSR protein
Immunohistochemical staining of VDR protein revealed
nuclear localization and that of CaSR protein revealed mainly
cytoplasmic localization. Representative figures are shown in
Figure 1. The labeling indices of the expressions of VDR
and CaSR protein in both uremic nodular hyperplasia and
recipients with nodular hyperplasia were significantly
Table 1 | Clinical features
Normal
Hemodialysis
patients
Renal allograft
recipients P-value
n 15 8 5 —
Age (years) 5573 5973 4872 NS
Duration of hemodialysis (months) NA 190746 139722 NS
Renal disease (CGN/DM/unknown) NA 4/2/2 3/0/2 —
Time between renal transplantation
and parathyroidectomy (months)
NA NA 1273 —
Serum corrected calcium (mg/dl) 9.170.1 10.770.2 12.370.5 o0.01
Serum phosphate (mg/dl) 3.770.1 5.570.3 2.570.2 o0.01
Serum alkaline phosphatase (U/l) 219715 7047102 506799 o0.05
Serum intact PTH (pg/ml) NA 10077120 187730 o0.01
CGN, chronic glomerulonephritis; DM, diabetes mellitus; n, number of specimens; NA, not available; PTH, parathyroid hormone.
Data are expressed as mean7s.e.m.
Table 2 | Parathyroid gland weight, labeling indices of VDR, CaSR, Ki67 antigen expression and TUNEL, and cell size index in
five parathyroid tissues obtained from each group
Group n
Parathyroid
gland weight (g)
VDR labeling
index (/1000 cells)
CaSR labeling
index (%)
Ki67 labeling
index (/1000 cells)
TUNEL labeling
index (/1000 cells)
Cell size
index (lm2/cell)
Normal glands 13 NA 6397203 50.372.9 471 271 12376
Hemodialysis patients
Diffuse hyperplasia 5 0.2370.10 224744* 29.372.3* 572 371 13176
Nodular hyperplasia 13 1.3270.36# 4278*,# 11.871.4*,# 2476*,# 772 200717*,#
Renal allograft recipients
Diffuse hyperplasia 10 0.0970.06 558771# 45.072.8# 573 3075*,# 12575
Nodular hyperplasia 11 0.4470.14yy 103745* 17.773.5* 771y 873 15577yy
CaSR, calcium-sensing receptor; NA, not available; TUNEL, TdT-mediated dUTP nick end labeling; VDR, vitamin D receptor.
Data are expressed as the mean7s.e.m.
*Po0.01 vs normal glands, #Po0.01 vs uremic diffuse hyperplasia, yPo0.01, yyPo0.05 vs uremic nodular hyperplasia.
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reduced compared with those of normal glands (Po0.01,
each). On the other hand, the expression levels in recipients
with diffuse hyperplasia were significantly higher than those
in uremic diffuse hyperplasia (Po0.01, each), being compar-
able with those of the control (Table 2).
Expression of Ki67 antigen
Ki67 antigen expression showed mainly nuclear localization
(Figure 2). Semiquantitative analysis demonstrated a sig-
nificantly higher Ki67 labeling index in uremic nodular
hyperplasia than in normal glands (Po0.01). On the other
hand, that of recipients with nodular hyperplasia was
comparable with that of the normal control, and was
significantly lower than that of patients with uremic nodular
hyperplasia (Po0.01).
In situ detection of DNA fragmentation
Analysis of parathyroid tissue by TdT-mediated dUTP nick
end labeling (TUNEL) technique revealed a distinct pattern
of nuclear staining in positive cells and negative cells
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Figure 1 | Representative immunohistochemical findings of VDR and CaSR protein expressions and of TUNEL assay in parathyroid
tissue of each group. (a–c) Normal parathyroid glands; (d–f) parathyroid glands of uremic patients showing diffuse hyperplasia; (g–i)
parathyroid glands of uremic patients with nodular hyperplasia; (j–l) parathyroid glands of recipient patients with diffuse hyperplasia; (m, n, o )
parathyroid glands of recipient patients with nodular hyperplasia; (a, d, g, j, m) VDR staining; (b, e, h, k, n) CaSR staining; (c, f, i, l, o) TUNEL
assay. Note the enhanced expression of VDR and CaSR protein in parathyroid gland of recipient with diffuse hyperplasia, compared with uremic
diffuse hyperplasia, being comparable with those in normal glands. Note the marked increase in TUNEL-positive cells in parathyroid gland of
recipient with diffuse hyperplasia. Original magnification  400.
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(Figure 1). Figure 1c, f, and i shows representative features in
normal glands and uremic diffuse and nodular hyperplasia,
respectively. A few apoptotic cells per high-power field
( 400 magnification) were noted. Figure 1l shows typical
features of a recipient with diffuse hyperplasia, demonstra-
ting the presence of large numbers of TUNEL-positive cells.
In recipients with nodular hyperplasia, only few TUNEL-
positive cells were encountered (Figure 1o). Table 2 lists the
average number of apoptotic cells per 1000 parathyroid cells
(labeling index) for each tissue group. The TUNEL labeling
index in recipients with diffuse hyperplasia was extremely
and significantly higher compared with other tissue groups
(Po0.01, each).
The differences in the labeling indices of Ki67 and TUNEL
were assessed in the five groups (Figure 3). The Ki67 labeling
index was equal to that of TUNEL in normal control, and was
higher than that of TUNEL in uremic nodular hyperplasia. In
recipients with diffuse hyperplasia, the TUNEL labeling index
was extremely higher than the Ki67 labeling index.
Assessment of parathyroid cell hypertrophy
Parathyroid cell volume in each tissue group was measured
by calculating the cell profile area divided by the cell number,
expressed as cell size index (Table 2). Representative
hematoxylin–eosin-stained sections are shown in Figure 4.
The cell profile area of patients with uremic nodular
hyperplasia was significantly larger than that of normal
glands and uremic patients with diffuse hyperplasia (Po0.01,
each). The cell size index of recipients with nodular
hyperplasia was comparably larger than that of the normal
control, but significantly smaller than that of patients with
uremic nodular hyperplasia (Po0.05). The index was
comparable between uremic and recipient patients with
diffuse hyperplasia.
DISCUSSION
The present study revealed that the diffuse hyperplastic
parathyroid glands of renal allograft recipient patients with
persistent secondary hyperparathyroidism show restoration
of VDR and CaSR expression, together with significant
apoptosis. Histopathological examination revealed that these
patients had at least more than one nodular hyperplastic
glands, considered as the causative nodules for the persistent
hyperparathyroidism. These results were compatible with the
previous reports, demonstrating that glands of patients with
persistent hyperparathyroidism after renal transplantation
contained more than one nodular hyperplasia.14,22 Restora-
tion of these sensing receptors was obvious only in diffuse
hyperplasia. It is well known that active vitamin D itself is a
strong factor for upregulation of VDR and CaSR expres-
sion,29,30 via vitamin D responsive element upstream of CaSR
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Figure 2 | Representative immunohistochemical findings of Ki67
antigen in parathyroid tissues with hematoxylin counterstaining.
Each parathyroid gland tissue showed nuclear staining for Ki67
antigen. (a) Normal glands; (b) parathyroid glands of uremic patients
with diffuse hyperplasia; (c) uremic nodular hyperplasia;
(d) parathyroid glands of recipient patients with diffuse hyperplasia;
and (e) parathyroid glands of recipient patients with nodular
hyperplasia. Ki67-positive cells in parathyroid glands of recipient
patients with diffuse and nodular hyperplasia were not enhanced,
being comparable with those in normal glands. In contrast,
Ki67-positive cells are markedly increased in uremic nodular
hyperplasia. Original magnification  400.
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Figure 3 | Microscopic findings of parathyroid tissues in each
group (hematoxylin staining). (a) Normal glands; (b) parathyroid
glands of uremic patients with diffuse hyperplasia; (c) parathyroid
glands of uremic patients with nodular hyperplasia;
(d) parathyroid glands of recipient patients diffuse hyperplasia;
and (e) parathyroid glands of recipient patients nodular hyperplasia.
Cell profile area of uremic nodular hyperplasia was large; however,
that of recipients’ nodular hyperplasia was comparably small.
Original magnification  400.
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gene.31 Thus, the recovery of active vitamin D production by
the transplanted kidney is considered to play a major role in
its process, and more importantly, the responsiveness of the
diffuse type of hyperplasia to active vitamin D was intact,
whereas it was lost in the nodular hyperplastic glands.
Indeed, serum vitamin D level of one recipient recovered to
normal level. It was also interesting to see that in spite of
comparatively low PTH level, bone turnover as well as serum
calcium levels increased in renal allograft recipients with
persistent hyperparathyroidism. These results suggest that the
skeletal resistance to PTH may recover after successful renal
transplantation.
Another important finding of the present study was the
reduced proliferative activity, as assessed by the expression of
Ki67 protein, in both types of hyperplasia in allograft
recipients. Ki67 expression in recipients with nodular
hyperplasia was also lower than in uremic nodular hyper-
plasia, being compatible with that in normal glands. Parfitt28
postulated that renal functional recovery after renal trans-
plantation might arrest further growth of parathyroid glands.
We demonstrated previously that the suppression of cyclin-
dependent kinase inhibitors, p21 and p27, in a vitamin
D-dependent manner was the main stream to parathyroid
gland hyperplasia.7 In diffuse hyperplasia, it is easily under-
stood that restoration of VDR improves the sensing
mechanism of active vitamin D, with a resultant inhibition
of cell cycle progression. In nodular hyperplasia, it means no
further glandular growth. However, the mechanism by which
Ki67 expression was reduced in nodular hyperplasia could
not be elucidated in the present study. It is speculated that
normalization of uremic milieu might play a role in
suppression of cell proliferation. Furthermore, the weight
of parathyroid glands of recipients with nodular hyperplasia
was lower than that of uremic patients with nodular
hyperplasia. Indeed, the cell volume expressed as cell size
index was significantly lower in this type of hyperplasia
compared with uremic nodular hyperplasia. These results
suggest that the former was less hypertrophic compared with
the latter. Nagano et al.32 reported that regression of cell
hypertrophy was the mechanism of regression of parathyroid
growth by sevelamer hydrochloride administration. Our
results suggest that serum Pi concentration might be related
to the mechanism of parathyroid cell hypertrophy. In the
present study, the low Pi levels in renal allograft recipients
were concordant with the above study.32
Abundant apoptotic cells were found in diffuse hyper-
plastic glands, promising future regression of hyperplastic
nodules. In the human parathyroid gland, Zhang et al.27
revealed that the number of apoptotic cells in secondary
parathyroid hyperplasia was significantly higher than in
normal parathyroid gland by using the TUNEL technique.
Our present results showed that the number of apoptotic cells
in nodular hyperplasia was not different from that of normal
glands, whereas it was extremely increased in diffuse
hyperplasia. Dru¨eke’s group27,33 examined the degree of
apoptosis and cell proliferation in human parathyroid gland.
Based on their data, they claimed that the rate of parathyroid
cell proliferation would be theoretically higher than that of
apoptosis in parathyroid hyperplasia of secondary hyper-
parathyroidism.26 According to this hypothesis, if regression
of hyperplastic glands really occurs, the rate of apoptosis
should have prevailed the rate of proliferation. We compared
directly the value of both TUNEL and Ki67 labeling indices
to assess the tendency of proliferation or regression (Figure 3).
TUNEL labeling index was significantly higher than Ki67
labeling index in recipients’ diffuse hyperplasia in the present
study. Thus, the hyperplastic parathyroid glands in uremic
patients could regress in certain conditions like after
successful renal transplantation. Fukagawa et al.34,35 sug-
gested regression of hyperplastic glands in response to oral
pulse therapy with active vitamin D in small-sized nodules,
that is, diffuse type of hyperplasia. These results suggest that
parathyroid hyperplasia of diffuse type may potentially
regress by inducing apoptosis. However, the exact factor that
might induce apoptosis could not be identified. Recently, in
VDR-expressing prostate cancer cell lines, it was revealed that
active vitamin D inhibited the expression of antiapoptotic
proteins, such as Bcl-2 and Bcl-XL, leading to activation of
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Figure 4 | Comparison of labeling indices of both Ki67 and TUNEL
among each histopathological type of parathyroid glands. In
uremic nodular hyperplasia, the labeling index of Ki67 prevailed over
that of TUNEL. These indices were comparable in normal glands,
parathyroid glands of uremic patients with diffuse hyperplasia, and
parathyroid glands of recipient patients with nodular hyperplasia.
Only in recipients’ diffuse hyperplasia, the labeling index of TUNEL
was extremely higher than that of Ki67.
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mitochondrial pathway that ultimately results in causing
apoptosis, whereas, in VDR-deficient prostate cell lines,
apoptosis was not induced.36 Based on this report, normali-
zation of active vitamin D–VDR system may be involved in
the induction of apoptosis in diffuse hyperplasia of
parathyroid glands. Considered together, these results suggest
that nodular hyperplasia does not show significant level of
apoptosis because its VDR expression remained low, having
little chance to regress. In the renal allograft recipients with
more than one nodular hyperplasia, PTH oversecretion
would continue owing to reduced sensing receptor and
increased parathyroid cell number, in spite of the recovery of
cell hypertrophy.
As reported in this study, renal allograft recipients with
severe persistent hyperparathyroidism are considered to have
more than one nodular parathyroid hyperplasia accompanied
by diminished expression of CaSR and/or VDR. Tominaga
et al.37 revealed that 90% of parathyroid glands weighing
more than 500 mg exhibit nodular formation. According to
this finding, if a recipient had at least one parathyroid gland
with an estimated weight of 500 mg at renal transplantation,
this gland would have no chance to regress and some
interventional therapy will be needed for the persistent
hyperparathyroidism. Vitamin D therapy is known to have an
effect on secondary hyperparathyroidism, but it would not be
suitable for persistent hyperparathyroidism because of the
side effect of hypercalcemia. A calcimimetic compound
might be useful for the treatment of this condition.38,39
However, when these therapies are ineffective, parathyroid-
ectomy is recommended.
In conclusion, the fate of hyperplastic glands in persistent
secondary hyperparathyroidism after renal transplantation
depends on its pattern of hyperplasia; the diffuse type of
hyperplasia has a strong tendency for regression. The
remaining large nodular hyperplasia indicates little possibility
of reversibility, requiring interventional treatment. Thus, if
conservative therapy (e.g. vitamin D or calcimimetics
supplementation) is ineffective, parathyroidectomy should
be considered in patients with hyperplastic glands weighing
more than 500 m2 detected by ultrasonography, to
prevent hypercalcemia-induced renal dysfunction and kidney
calcification.
MATERIALS AND METHODS
Clinical characteristics of patients
The subjects of the present study were renal allograft recipients
with uncontrollable hypercalcemia and markedly elevated PTH
after achieving normal renal function. Clinical history and
follow-up information were carefully investigated in each patient,
including age, preoperative serum level of Ca, Pi, alkaline
phosphatase, and intact PTH. Parathyroid gland weight was
measured following surgical resection. All allograft recipients with
persistent secondary hyperparathyroidism had a stable renal
function (serum creatinine concentration o1.5 mg/dl), and were
not treated with vitamin D sterol owing to severe hypercalcemia.
One recipient was treated with alendronate for high bone turnover,
but it was ineffective.
The tissue samples of parathyroid glands were obtained at
Kyushu University Hospital between 1995 and 2003 at the time of
surgery from patients with renal allograft and persistent hyper-
parathyroidism, patients on hemodialysis with severe secondary
hyperparathyroidism, and patients with Graves’ disease. The
parathyroid glands that were obtained included 13 normal glands,
and according to the pattern of hyperplasia, 18 glands were
subdivided into diffuse and nodular ones in each patient category,
with a total of five with diffuse hyperplasia and 13 with nodular
hyperplasia from patients on hemodialysis, and 10 with diffuse
hyperplasia and 11 with nodular hyperplasia from allograft
recipients.
Immunohistochemical analyses of CaSR/VDR receptors and
cell proliferation
All specimens were fixed in 10% formalin and routinely processed
with paraffin. Formalin-fixed, paraffin-embedded tissue sections
were serially cut at 3 mm thickness and mounted on aminopropyl-
triethoxysilane-coated glass slides. The sections were deparaffinized
in xylene and dehydrated through a series of ethanol solution.
Immunohistochemical staining was performed as described
previously.7 The sections were treated with 10 mM citrate, pH 6.0,
in a microwave oven for antigen retrieval before immuno-
histochemical staining. They were also pretreated with 5% skim
milk at room temperature for 1 h to block nonspecific binding of the
primary antibodies. The serial sections were then incubated
overnight with the primary antibodies at 41C. The used antibodies
included anti-CaSR antibody (Affinity Bioreagents Inc., CO, USA)
at 1/100 dilution, anti-VDR antibody (Biomeda Laboratories,
CA, USA) at 1/500 dilution, and anti-Ki67 antibody (Novocastra
Laboratories, Newcastle, UK) at a 1/100 dilution. Ki67 antigen
is a nuclear protein expressed in proliferating cells and required
for cell proliferation. Immunostaining was performed with the
Elite avidin biotin peroxidase kit (Nichirei, Tokyo, Japan) according
to the specifications provided by the manufacturer. Quantitative
analysis was performed using immunohistochemically stained
serial sections.
TUNEL assay
Fragmented DNA was detected in cell nuclei using the method
described previously27 with some modifications. Paraffin sections of
parathyroid tissue were deparaffinized and dehydrated. Then, after
blocking with 0.3% H2O2 in methanol for 30 min at room
temperature, 50 ml of TUNEL reaction mixture (10 Tdt 50 ml,
1 nucleotide mixture 450ml, in situ cell death detection kit, POD:
Roche, Mannheim, Germany) was added to each section and
incubated in a moist chamber at 371C for 1 h. Subsequently, 50 ml of
converter POD (anti-fluorescein antibody, Fab fragment from
sheep, conjugated with horseradish peroxidase) was applied to
each specimen, and the slides were incubated for 30 min at 371C
in a humidified chamber. After reaction with converter POD,
the sites of horseradish peroxidase were visualized with 3,3-
diaminobenzidine and H2O2. Slides were counterstained with
methyl green for 2 min.
Quantitative analysis
The method used for quantitative analysis was described previously.7
Briefly, only clear immunostaining for CaSR, VDR, Ki67, and
TUNEL was considered positive immunoreactivity. The distribution
of immunoreactivity was analyzed by quantifying positive staining
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in randomly selected areas in each specimen without prior
knowledge of either diagnosis or outcome. The numbers of VDR-,
Ki67-, and TUNEL-expressing cells were determined by counting a
minimum of 1000 cells per slide using NIH image analysis freeware.
The brightness and contrast of each image were uniformly enhanced
or subtracted by Photoshop version 5.0 (Adobe, San Jose, CA, USA)
followed by analysis using NIH image freeware version 1.62. With
regard to VDR, Ki67, and TUNEL staining, in order to avoid the
influence of nonspecific positive staining, plots of less than 30 pixels
were excluded. The percentage of positive immunoreactive area per
total area (CaSR) and the number of positive immunoreactive nuclei
per 1000 parenchymal cells (VDR, Ki67, and TUNEL) were
expressed as the labeling index. CaSR, VDR, Ki67, and TUNEL
immunoreactive cells were randomly counted over a minimum of
five fields in more than three sections. Repeat recounts for CaSR,
VDR, Ki67, and TUNEL in 10% of the parathyroid glands
conducted in a blind fashion showed variability of labeling index
of less than 75% from the original counts.
Assessment of cell hypertrophy
In order to assess the cell hypertrophy, the area of one cell was
calculated in hematoxylin-stained sections and expressed as cell size
index by using the following formula: cell size index (mm2/cell)¼T
(mm2)/N, where T is the total area of the visual field and N is the
total number of parathyroid cells per visual field.
Statistical analysis
Data are expressed as mean7s.e.m. All statistical analyses
were conducted using the StatView program (Abacus Concepts,
Berkeley, CA, USA). One-way analysis of variance was used
followed by Student’s t-test with Bonferroni correction when
indicated for comparison of histological findings between two
groups. A P-value less than 0.05 was considered statistically
significant.
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